Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TNKS | O95271 | 1/20 | 0.36 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 6/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL104637 | 0.77 | LMNA (0.56) | LMNAMEN1KMT2ATNKSPTGER3 | |
| SCHEMBL103819 | 0.74 | LMNA (0.56) | LMNAMEN1KMT2ATNKSPTGER3 | |
| SCHEMBL104830 | 0.72 | LMNA (0.41) | LMNAMEN1KMT2APTGER3 | |
| SCHEMBL105693 | 0.69 | AKR1B1 (0.43) | LMNAMEN1KMT2AAKR1B1 | |
| SCHEMBL1100833 | 0.69 | AKR1B1 (0.42) | LMNAMEN1KMT2ATNKSAKR1B1 | |
| SCHEMBL20135575 | 0.68 | MEN1 (0.48) | LMNAMEN1KMT2ATNKS | |
| SCHEMBL542484 | 0.67 | LMNA (0.70) | LMNAMEN1KMT2ATNKSPTGER3 | |
| SCHEMBL3915449 | 0.67 | LMNA (0.57) | LMNAMEN1KMT2ATNKS | |
| SCHEMBL1092622 | 0.65 | MEN1 (0.45) | LMNAMEN1KMT2ATNKSPTGER3 | |
| SCHEMBL105065 | 0.65 | LMNA (0.55) | LMNAMEN1KMT2ATNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153634-B2 | Carbinol derivatives having cyclic linker | KOWA COMPANY, LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| EP-2281817-A1 | SUBSTITUTED CARBINOL COMPOUND HAVING CYCLIC LINKER | Kowa Company, Ltd. (JP) | 2011-02-09 | — | — | EP | disclosed |
| US-20100048610-A1 | CARBINOL DERIVATIVES HAVING CYCLIC LINKER | KOWA COMPANY, LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048610-A1 | CARBINOL DERIVATIVES HAVING CYCLIC LINKER | NR1H2, NR1H3, LDLR | LMNA 1288/4885MEN1 3823/4885KMT2A 2383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.